Neil Chanchlani, Simeng Lin, Marcus K Auth, Chai Leng Lee, Helena Robbins, Shi Looi, Senthil V Murugesan, Tom Riley, Cathryn Preston, Sophie Stephenson, Wendy Cardozo, Sunil A Sonwalkar, Mohammed Allah-Ditta, Lynne Mansfield, Dharmaraj Durai, Mark Baker, Ian London, Emily London, Sanjay Gupta, Alex Di Mambro, Aisling Murphy, Edward Gaynor, Kelsey D J Jones, Andrew Claridge, Shaji Sebastian, Sankaranarayanan Ramachandran, Christian P Selinger, Simon P Borg-Bartolo, Paul Knight, Michael B Sprakes, Julie Burton, Patricia Kane, Stephanie Lupton, Aimee Fletcher, Daniel R Gaya, Roghan Colbert, John Paul Seenan, Jonathan MacDonald, Lucy Lynch, Iain McLachlan, Stephanie Shields, Richard Hansen, Lisa Gervais, Mwansa Jere, Muhammad Akhtar, Karen Black, Paul Henderson, Richard K Russell, Charlie W Lees, Lauranne A A P Derikx, Melanie Lockett, Frederica Betteridge, Aminda De Silva, Arif Hussenbux, John Beckly, Oliver Bendall, James W Hart, Amanda Thomas, Ben Hamilton, Claire Gordon, Desmond Chee, Timothy J McDonald, Rachel Nice, Marian Parkinson, Helen Gardner-Thorpe, Jeff R Butterworth, Asima Javed, Sarah Al-Shakhshir, Rekha Yadagiri, Sebrene Maher, Richard C G Pollok, Tze Ng, Priscilla Appiahene, Fiona Donovan, James Lok, Rajiv Chandy, Reema Jagdish, Daniyal Baig, Zahid Mahmood, Liane Marsh, Allison Moss, Amin Abdulgader, Angus Kitchin, Gareth J Walker, Becky George, Yuen-Hui Lim, James Gulliver, Stuart Bloom, Holly Theaker, Sean Carlson, J R Fraser Cummings, Robert Livingstone, Amanda Beale, Josiah O Carter, Andrew Bell, Archibald Coulter, Jonathon Snook, Helen Stone, Nicholas A Kennedy, James R Goodhand, Tariq Ahmad
BACKGROUND: Anti-drug antibodies are associated with treatment failure to anti-TNF agents in patients with inflammatory bowel disease (IBD). AIM: To assess whether immunogenicity to a patient's first anti-TNF agent would be associated with immunogenicity to the second, irrespective of drug sequence METHODS: We conducted a UK-wide, multicentre, retrospective cohort study to report rates of immunogenicity and treatment failure of second anti-TNF therapies in 1058 patients with IBD who underwent therapeutic drug monitoring for both infliximab and adalimumab...
October 2022: Alimentary Pharmacology & Therapeutics